ADVERSE EVENTS ASSOCIATED WITH COLCHICINE DRUG INTERACTIONS: ANALYSIS OF THE PUBLIC VERSION OF THE FDA ADVERSE EVENT REPORTING SYSTEM

被引：0
|
作者：
Almalki, Z. [1 ]
Guo, J. J. [1 ]
Kelton, C. M. [2 ]
Wigle, P. R. [1 ]
机构：
[1] Univ Cincinnati, Coll Pharm, Cincinnati, OH 45267 USA
[2] Univ Cincinnati, Coll Business, Cincinnati, OH USA
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
10.1016/j.jval.2013.03.1105
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A218 / A218
页数：1
相关论文
共 50 条
  • [1] Adverse Events Associated with Colchicine Drug Interactions: Analysis of the Public Version of the FDA Adverse Event Reporting System
    Almalki, Ziyad S.
    Guo, Jeff J.
    Kelton, Christina M. L.
    Wigle, Patricia R.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 83 - 84
  • [2] Statin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System
    Sakaeda, Toshiyuki
    Kadoyama, Kaori
    Okuno, Yasushi
    [J]. PLOS ONE, 2011, 6 (12):
  • [3] Vedolizumab Adverse Events: Analysis of the FDA Adverse Event Reporting System
    Jow, Steven
    Hutfless, Susan
    [J]. INFLAMMATORY BOWEL DISEASES, 2017, 23 : S35 - S36
  • [4] Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Xiong, Xiaomei
    Zhang, Xiuwen
    Li, Xiaoxia
    Huang, Taomin
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [5] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Shu-peng Zou
    Hai-yun Yang
    Meng-ling Ouyang
    Qian Cheng
    Xuan Shi
    Ming-hui Sun
    [J]. BMC Pharmacology and Toxicology, 24
  • [6] Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
    Shu, Yamin
    Ding, Yiling
    Liu, Lulu
    Zhang, Qilin
    [J]. CNS NEUROSCIENCE & THERAPEUTICS, 2023, 29 (09) : 2705 - 2716
  • [7] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Zou, Shu-peng
    Yang, Hai-yun
    Ouyang, Meng-ling
    Cheng, Qian
    Shi, Xuan
    Sun, Ming-hui
    [J]. BMC PHARMACOLOGY & TOXICOLOGY, 2023, 24 (01):
  • [8] Data Mining of the Public Version of the FDA Adverse Event Reporting System
    Sakaeda, Toshiyuki
    Tamon, Akiko
    Kadoyama, Kaori
    Okuno, Yasushi
    [J]. INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2013, 10 (07): : 796 - 803
  • [9] DRUGS ASSOCIATED WITH ADVERSE DRUG EVENTS IN CHILDREN: ANALYSIS OF THE UNITED STATES FDA ADVERSE EVENT REPORTING SYSTEM DATABASE
    Lee, W. J.
    Schumock, G. T.
    Lee, T. A.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A70 - A70
  • [10] Cardiovascular adverse events associated with parp inhibitors: A disproportionality analysis of FDA adverse event reporting system
    Viswam, Subeesh Kulangara
    Kheterpal, Aarushi
    Dhas, Ashwin
    Zeba, Zeba
    Shettigar, Amrutha
    Lukose, Lipin
    Kaur, Gursimran
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 452 - 452
12345